Merck announced on Friday that the Committee of Experts (CHMP) of the European Medicines Agency (EMA) had issued a positive opinion on the marketing authorization application for Winrevair.

The CHMP recommends approval of Winrevair for the treatment of pulmonary arterial hypertension in patients with WHO functional class II and III, in combination with other medicines for exercise rehabilitation.

The European Commission (EC) will examine the CHMP's recommendation, which it generally follows, and will make a final decision on the marketing of Winrevair in the European Union, Iceland, Liechtenstein and Norway during the third quarter.

This drug was already approved in the United States in March.

Copyright (c) 2024 CercleFinance.com. All rights reserved.